1. Scrip
  2. >>Business
  3. >>Deals

Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program

 
• By Joseph Haas and Jung Won Shin

Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.

Tech Transfer regular column feature image

Shortly after arriving at University of California, San Diego as its director of commercialization, Ruben Dario Flores-Saaib initiated an “entrepreneurs in residence” program that in two years helped spur the creation of five start-ups around research conducted at the school.

Flores-Saaib, a 12-year biopharma industry veteran who helped establish and lead a bioscience academic alliances team at Merck KGAA/EMD Millipore for five years, told Scrip the entrepreneurs in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.